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Sexual transmission of HIV-1 is currently the major way of viral spread worldwide: the 63	  
quantification of HIV-1 RNA has been clearly linked to the risk of transmission.1 The use of highly 64	  
active antiretroviral treatment (HAART) besides providing immunovirological benefits has been 65	  
associated with viral control in the genital compartment of males and females. Nevertheless 66	  
occasional HIV-1 shedding has been demonstrated despite effective systemic therapy: insufficient 67	  
penetration of antiretrovirals has been advocated as one of the reasons for HIV-1 68	  
compartimentalization.2 Although dual and mono-therapies have been shown to be effective in the 69	  
majority of stable HIV-positive patients although limited data exists on their effectiveness in the 70	  
genital compartment.3 Furthermore maraviroc dosage when administered with boosted protease 71	  
inhibitors is still debated: 150 mg once-daily showed promising antiviral efficacy when combined 72	  
with lopinavir/ritonavir and lower than expected results in association with atazanavir/ritonavir and 73	  
darunavir/ritonavir.4,5 Primary aim of this study was to describe the seminal pharmacokinetics of 74	  
maraviroc (150 mg once-daily) when given in association with lopinavir/ritonavir; secondary 75	  
objective was to analyze seminal HIV-1 replication in patients receiving this dual regimen. 76	  
Adult male patients enrolled in the VEMAN protocol4 were eligible for this sub-study. Main 77	  
inclusion criteria were no concomitant systemic nor genital illness, a confirmed viral load below 37 78	  
copies/mL, to be on protocol between weeks 48 and 96, and no coadministration of potentially 79	  
interacting drugs. A written informed consent was signed by each participant after approval by the 80	  
San Raffaele Scientific Institute Ethics Committee, Milano, Italy. Blood plasma and seminal plasma 81	  
levels were measured by a validated ultra-performance liquid chromatography coupled with triple-82	  
quadrupole mass spectrometry method (UPLC-MS-MS) with a limit of detection of 0.125 ng/mL. 83	  
Plasma HIV RNA was measured through kinetic PCR molecular system (kPCR) (Versant HIV-1 84	  
RNA kPCR 1.0; Siemens Diagnostics) with a limit of quantification o 37 copies/mL; seminal 85	  
plasma HIV RNA was measured through a NASBA™-based real-time amplification, the NucliSENS 86	  
EasyQ®	  HIV-1 v2.0 (with a detection rate of 79% at 500 copies/mL).6 Chi square and Mann-Whiney 87	  
tests were used to test differences between variables while Spearman's rho was used to quantify 88	  
correlations significance. Data are expressed as medians (interquartile ranges); coefficient of 89	  
variation was calculated as standard deviation/average.  90	  
Ten male patients were enrolled [aged 39.6 years (34.3-45.8) and with a body mass index of 23.5 91	  
mg/Kg2 (22.2-29.4)]. All patients had a HIV RNA <37 copies/mL and CD4 cell count was 619/uL 92	  
(547-683). Plasma and seminal samples were collected respectively 11.6 (10.1-12.4) and 9.2 (8-93	  
11.5) hours after maraviroc intake. Maraviroc plasma and seminal concentrations were 223 ng/mL 94	  
(103.9-312, 55.4%) and 527 ng/mL (234-852, 89.8%): seminal plasma to plasma ratio (ratioSP-P) 95	  
was 291.6% (103.9-405.1, 80.5%) (Figure). Lopinavir plasma and seminal concentrations were 96	  
7935 ng/mL (6269-8958) and 233 ng/mL (136-803): lopinavir ratioSP-P was 4.3% (2.6-11.7). 97	  
Ritonavir plasma and seminal concentrations were 275 ng/mL (224-773) and 21 ng/mL (7-31): 98	  
ritonavir ratioSP-P was 8.3% (IQR 4.6-10.7). 99	  
The included patients were compared to five patients in the control arm (receiving 100	  
tenofovir/emtricitabina plus lopinavir/ritonavir): male, with median age, BMI and CD4 cell count of 101	  
43 years (37.3-44), 22.3 kg/m2 (21.5-24.8) and 480/uL (449-531). Lopinavir plasma and seminal 102	  
concentrations and ratioSP-P were 11521 ng/mL (10111-14018), 517 ng/mL (461-634) and 6.3% 103	  
(3.3-6.6). Ritonavir plasma and seminal concentrations and ratioSP-P were 436 ng/mL (424-900), 18 104	  
ng/mL (16-35) and 6.2% (1.3-8.1). While RNA amplification was not effective in two samples, 105	  
seminal HIV RNA was undetectable in all the other ones (n=13). 106	  
This is the first report of maraviroc pharmacokinetics in seminal plasma when dosed at 150 mg 107	  
once-daily with a boosted PI. Maraviroc confirmed to accumulate in seminal plasma and 108	  
compartmental maraviroc concentrations were found to be adequate, well above the protein-free 109	  
IC90 (0.5 ng/mL) in all included subjects. 110	  
Lopinavir and ritonavir exposures in seminal plasma were similar to previous reports. In  previous 111	  
studies maraviroc administered twice-daily (150, 300 or 600 mg)7-10 showed median seminal 112	  
concentrations between 80 and 804 ng/mL, being 89% to 970% of plasma levels with a large inter-113	  
patient variability (seminal levels ranging from 15.8 ng/mL to 4920 ng/mL). Interestingly in our 114	  
patients both plasma and seminal maraviroc exposure resulted to be comparable to the values 115	  
previously reported for maraviroc at double dosing (150 mg bid) with darunavir/r. This finding 116	  
further supports the pharmacological suitability of once-daily dosing maraviroc 150 mg with 117	  
lopinavir/ritonavir. Moreover, pharmacological findings were consistent with virological data:  both 118	  
in patients in the experimental dual regimen arm and in the triple drug arm seminal plasma HIV 119	  
RNA was undetectable. These data support the seminal virological effectiveness of once-daily 120	  
maraviroc plus LPV/r association and confirm, in general terms, the result of previous data on PI-121	  
based dual regimens in the male genital tract3. 122	  
In conclusion, once-daily maraviroc at 150 mg administered with with lopinavir/ritonavir showed 123	  



















Figure. Maraviroc seminal pharmacokinetics. Plasma, and seminal plasma concentrations (left) 135	  
(horizontal lines represent median and interquartile range values). Seminal plasma to plasma ratios 136	  
(right): horizontal line represents median values; box and whiskers respectively represent 137	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